Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation-Reference-Cited by-同舟云学术

Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation

Published:2017-10 Issue:10 Volume:121 Page:1025-1030
ISSN:0168-8510
Container-title:Health Policy
language:en
Short-container-title:Health Policy

Author:

Towse Adrian,Hoyle Christopher K.,Goodall Jonathan,Hirsch Mark,Mestre-Ferrandiz Jorge,Rex John H.

Publisher

Elsevier BV

Subject

Health Policy

Reference40 articles.

1. R&D costs and returns by therapeutic category;DiMasi;Drug Information Journal,2004

2. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories;Falagas;PLoS One,2006

3. Returns on research and development for 1990 new drug introductions;Grabowski;Pharmacoeconomics,2002

4. Why is big Pharma getting out of antibacterial drug discovery?;Projan;Current Opinion in Microbiology,2003

5. New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options;Sharma,2011

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of green-synthesized silver nanoparticle-loaded graphene oxide (AgNPs@GO) nanocomposite toward bio logical wastewater filtration;Case Studies in Chemical and Environmental Engineering;2024-12

2. A Foundation Model Identifies Broad-Spectrum Antimicrobial Peptides against Drug-Resistant Bacterial Infection;Nature Communications;2024-08-30

3. Antimicrobial use in laboratory rodent facilities in Australia and New Zealand- a cross-sectional survey of veterinarians and facility managers;PLOS ONE;2024-08-23

4. New Agents Are Coming, and So Is the Resistance;Antibiotics;2024-07-13

5. Inhalable Polymeric Microparticles for Phage and Photothermal Synergistic Therapy of Methicillin-Resistant Staphylococcus aureus Pneumonia;Nano Letters;2024-07-02